Michael Rassner
Overview
Explore the profile of Michael Rassner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borst N, Ihorst G, Wenger S, Rader J, Wasch R, Engelhardt M, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682276
In recent years, there have been significant advances in the understanding and treatment of multiple myeloma (MM). Despite this progress, there is still limited information on the disease in patients...
2.
Maas-Bauer K, Stell A, Yan K, de Vega E, Vinnakota J, Unger S, et al.
Nat Commun
. 2024 Jan;
15(1):446.
PMID: 38199985
Patients with corticosteroid-refractory acute graft-versus-host disease (aGVHD) have a low one-year survival rate. Identification and validation of novel targetable kinases in patients who experience corticosteroid-refractory-aGVHD may help improve outcomes. Kinase-specific...
3.
Rassner M, Waldeck S, Follo M, Jilg S, Philipp U, Jolic M, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982486
Background: Mutations in cKIT or PDGFRA are found in up to 90% of patients with gastrointestinal stromal tumors (GISTs). Previously, we described the design, validation, and clinical performance of a...
4.
Frank B, Ihorst G, Herget G, Schafer H, Neubauer J, Calba M, et al.
Ann Hematol
. 2022 Dec;
102(3):603-611.
PMID: 36464695
The established standard to ensure state-of-the-art cancer treatment is through multidisciplinary tumor boards (TBs), although resource- and time-intensive. In this validation study, the multiple myeloma (MM)-TB was reexamined, aiming to...
5.
Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, et al.
Am J Hematol
. 2022 Apr;
97(7):877-884.
PMID: 35389534
Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity. Literature regarding treatment and its outcomes in MGRS is sparse due to the rarity and misdiagnosis of MGRS. We...
6.
Jakob L, Muller T, Rassner M, Kleinfelder H, Veratti P, Mitschke J, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34769079
The IL-6 family cytokine Oncostatin M (OSM) is involved in cell development, growth, hematopoiesis, inflammation, and cancer. Intriguingly, OSM has proliferative and antiproliferative effects depending on the target cell. The...
7.
Waldeck S, Mitschke J, Wiesemann S, Rassner M, Andrieux G, Deuter M, et al.
Mol Oncol
. 2021 Oct;
16(2):527-537.
PMID: 34653314
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non-small-cell lung cancer (NSCLC). However,...
8.
Riebl V, Dold S, Wider D, Follo M, Ihorst G, Waldschmidt J, et al.
Front Oncol
. 2021 Sep;
11:708231.
PMID: 34485145
Objective: In clinical trials (CTs), the assessment of minimal residual disease (MRD) has proven to have prognostic value for multiple myeloma (MM) patients. Multiparameter flow cytometry (MFC) and next-generation sequencing...
9.
Shoumariyeh K, Jung J, Rassner M, Dold S, Riebl V, Pantic M, et al.
Ann Hematol
. 2021 Mar;
100(6):1637-1640.
PMID: 33712868
No abstract available.
10.
Engelhardt M, Ihorst G, Schumacher M, Rassner M, Gengenbach L, Moller M, et al.
BMC Cancer
. 2021 Feb;
21(1):173.
PMID: 33596881
Background: The standard to ensure utmost cancer treatment is a prerequisite in national cancer plans for comprehensive cancer centers (CCCs) and ensured through multidisciplinary tumor boards (MTBs). Despite these being...